echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Shortage Drug List is here!

    The Shortage Drug List is here!

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The four departments jointly issued a document requesting to strengthen the monitoring of the production and reserve of drugs in shortage and selected drugs selected by the state
    .
    Among them, there are 109 shortage drug preparations, 60 shortage drug raw materials, 240 nationally selected drugs, and 10 shortage drug reserve enterprises
    .
    The reporting time for monitoring information is the 10th of each month.
    For enterprises that fail to comply with the requirements, they will be interviewed and required to rectify within a time limit
    .
     
    On August 9, the Ministry of Industry and Information Technology, the National Health and Health Commission, the National Medical Insurance Administration, and the State Food and Drug Administration jointly issued the "Notice on Strengthening the Monitoring of Shortaged Drugs and the Production and Reserve Monitoring of Selected Drugs in Centralized Procurement of Drugs Organized by the State", in order to timely determine the shortage of drugs and national The risk of shortage of selected drugs will be improved, the production and supply guarantee capacity of related drugs will be improved, and the production and reserves of enterprises involved will be included in the key monitoring, and they will be required to fill in relevant monitoring information online before the 10th of each month
    .
     
    The monitoring varieties involved include the national shortage drugs, the national key monitoring list of clinically necessary drugs that are prone to shortage, and the national centralized procurement of selected varieties
    .
    The catalogue of monitored varieties and the catalogue of enterprises are dynamically adjusted
    .
     
    With the normalization of national centralized procurement, for enterprises, not only the price requirements, but also the stable supply is increasingly valued, and the previous incident of the interruption of the supply of ibuprofen sustained-release capsules of North China Pharmaceuticals also brought a lot of attention to the industry.
    Great impact, but also sounded the alarm for the subsequent formulation of national procurement rules
    .
     
    In the seventh batch of national centralized procurement, which was launched not long ago, innovative rules for supplying areas appeared for the first time.
    It is not difficult to see that the purpose is to avoid the risk of "discontinued supply" that has occurred in the past few rounds of centralized procurement
    .
    The issuance of this document includes the production reserves of the selected enterprises in the national procurement into the monitoring, which is also to further ensure the smooth progress of the national procurement
    .
     
      As for the stable supply and price of drugs in short supply, the state and local governments are also continuously improving the multi-departmental drug information collaborative monitoring mechanism, improving the supply level of drugs in multiple dimensions, and strengthening the supply and monitoring of key drugs
    .
     
      On May 27, 2022, the official website of the National Health Commission of the People's Republic of China published the "Recent Work on Sustaining Supply and Stable Prices of Drugs in Shortage", which stated that "tailor-made" practical and effective solutions to the problem of drug shortages caused by different reasons will ensure the basic clinical practice.
    Medication needs
    .
    In addition, strengthen the normalized supervision and information feedback of drug prices, fully mobilize the resources of all parties, deal with the problem of drug shortages and public opinions, and increase the penalties for violations of laws and regulations
    .
     
      It is believed that with the continuous improvement of the regulatory mechanism, the supply of drugs in national shortage or selected drugs will be further guaranteed
    .
     
      Monitoring varieties: 109 short-listed preparations, 60 short-listed raw materials, and 240 nationally selected drugs
     
      The monitored varieties are the varieties on the National Shortage Drug List announced by the National Health and Medical Commission, the National Key Monitoring List of Clinically Necessary Drugs that are prone to Shortage, and the selected drugs in the centralized procurement of nationally organized drugs announced by the National Medical Insurance Administration
    .
    The catalogue of monitored varieties will be dynamically adjusted
    .
     
      Monitoring enterprises: 10 shortage drug reserve enterprises
     
      The monitoring enterprises include the production enterprises of shortage drugs, the enterprises selected for centralized procurement of drugs organized by the state, and the key shortage drug reserve enterprises (for details, please refer to the attached table at the end of the article)
    .
    Monitor the implementation of dynamic adjustments to the enterprise directory
    .
     
      Monitoring working mode:
     
      Local industry and informatization authorities, together with health , medical security, and drug regulatory authorities, urge and guide monitoring companies in the region to fill in production reserve information online, and coordinate and organize production and supply
    .
    The Ministry of Industry and Information Technology, together with relevant departments, analyzes production reserve information, conducts inspections and assessments in a timely manner, publishes relevant information, and coordinates and solves major problems
    .
     
      When and how to submit information:
     
      Before the 10th of each month, the manufacturers of drugs in shortage and the manufacturers of selected drugs in centralized procurement shall, through the "Monitoring and Early Warning Platform for Production and Supply of Shortaged Drugs" (website), fill in the " Monitoring Report on Production and Supply of Drugs in Shortage of Pharmaceutical Industry Enterprises " and "National Centralized Procurement of Drug Production " respectively.
    Supply Monitoring Report"; key drug reserve enterprises in shortage fill in the " Statistical Table of Inventory Quantity of Shortage Drugs " through the "National Medical Reserve Management Information System"
    .
     
      Establish and improve the monitoring information reporting system, and must not be late or reported
     
      Manufacturers of drugs in short supply and selected drugs in centralized procurement are the first responsible person for reporting production reserve monitoring information.
    It is necessary to establish and improve the monitoring information submission work system; designate a person to fill in the production reserve data in a true, accurate, complete and timely manner without delay or delay.
    Refuse to report; cooperate with relevant departments in the investigation of drug shortage incidents, and provide information required for the investigation; set up production and supply inventory safety warning lines and prepare response plans
    .
     
      For enterprises that fail to comply with the requirements, they will be interviewed and required to rectify within a time limit as the case may be
    .
     
      Strengthen supervision and management.
    The local industry and information technology department, together with relevant departments, is responsible for the production and reserve monitoring of drugs in short supply and centralized procurement in the region, organizes enterprises to submit relevant data, audits the integrity and accuracy of data, and strengthens the supervision of drugs.
    Quality supervision and inspection, and urge production enterprises to implement their responsibilities for sufficient supply and stop production reports in accordance with the purchase agreement
    .
    For enterprises that fail to comply with the requirements, they will be interviewed and required to rectify within a time limit as the case may be
    .
      The four departments jointly issued a document requesting to strengthen the monitoring of the production and reserve of drugs in shortage and selected drugs selected by the state
    .
    Among them, there are 109 shortage drug preparations, 60 shortage drug raw materials, 240 nationally selected drugs, and 10 shortage drug reserve enterprises
    .
    The reporting time for monitoring information is the 10th of each month.
    For enterprises that fail to comply with the requirements, they will be interviewed and required to rectify within a time limit
    .
     
      On August 9, the Ministry of Industry and Information Technology, the National Health and Health Commission, the National Medical Insurance Administration, and the State Food and Drug Administration jointly issued the "Notice on Strengthening the Monitoring of Shortaged Drugs and the Production and Reserve Monitoring of Selected Drugs in Centralized Procurement of Drugs Organized by the State", in order to timely determine the shortage of drugs and national The risk of shortage of selected drugs will be improved, the production and supply guarantee capacity of related drugs will be improved, and the production and reserves of enterprises involved will be included in the key monitoring, and they will be required to fill in relevant monitoring information online before the 10th of each month
    .
     
      The monitoring varieties involved include the national shortage drugs, the national key monitoring list of clinically necessary drugs that are prone to shortage, and the national centralized procurement of selected varieties
    .
    The catalogue of monitored varieties and the catalogue of enterprises are dynamically adjusted
    .
     
      With the normalization of national centralized procurement, for enterprises, not only the price requirements, but also the stable supply is increasingly valued, and the previous incident of the interruption of the supply of ibuprofen sustained-release capsules of North China Pharmaceuticals also brought a lot of attention to the industry.
    Great impact, but also sounded the alarm for the subsequent formulation of national procurement rules
    .
     
      In the seventh batch of national centralized procurement, which was launched not long ago, innovative rules for supplying areas appeared for the first time.
    It is not difficult to see that the purpose is to avoid the risk of "discontinued supply" that has occurred in the past few rounds of centralized procurement
    .
    The issuance of this document includes the production reserves of the selected enterprises in the national procurement into the monitoring, which is also to further ensure the smooth progress of the national procurement
    .
     
      As for the stable supply and price of drugs in short supply, the state and local governments are also continuously improving the multi-departmental drug information collaborative monitoring mechanism, improving the supply level of drugs in multiple dimensions, and strengthening the supply and monitoring of key drugs
    .
     
      On May 27, 2022, the official website of the National Health Commission of the People's Republic of China published the "Recent Work on Sustaining Supply and Stable Prices of Drugs in Shortage", which stated that "tailor-made" practical and effective solutions to the problem of drug shortages caused by different reasons will ensure the basic clinical practice.
    Medication needs
    .
    In addition, strengthen the normalized supervision and information feedback of drug prices, fully mobilize the resources of all parties, deal with the problem of drug shortages and public opinions, and increase the penalties for violations of laws and regulations
    .
     
      It is believed that with the continuous improvement of the regulatory mechanism, the supply of drugs in national shortage or selected drugs will be further guaranteed
    .
     
      Monitoring varieties: 109 short-listed preparations, 60 short-listed raw materials, and 240 nationally selected drugs
     
      The monitored varieties are the varieties on the National Shortage Drug List announced by the National Health and Medical Commission, the National Key Monitoring List of Clinically Necessary Drugs that are prone to Shortage, and the selected drugs in the centralized procurement of nationally organized drugs announced by the National Medical Insurance Administration
    .
    The catalogue of monitored varieties will be dynamically adjusted
    .
     
      Monitoring enterprises: 10 shortage drug reserve enterprises
    Monitoring enterprises: 10 shortage drug reserve enterprises
     
      The monitoring enterprises include the production enterprises of shortage drugs, the enterprises selected for centralized procurement of drugs organized by the state, and the key shortage drug reserve enterprises (for details, please refer to the attached table at the end of the article)
    .
    Monitor the implementation of dynamic adjustments to the enterprise directory
    .
     
      Monitoring working mode:
    Monitoring working mode:
     
      Local industry and informatization authorities, together with health , medical security, and drug regulatory authorities, urge and guide monitoring companies in the region to fill in production reserve information online, and coordinate and organize production and supply
    .
    The Ministry of Industry and Information Technology, together with relevant departments, analyzes production reserve information, conducts inspections and assessments in a timely manner, publishes relevant information, and coordinates and solves major problems
    .
    healthy and healthy
     
      When and how to submit information:
    When and how to submit information:
     
      Before the 10th of each month, the manufacturers of drugs in shortage and the manufacturers of selected drugs in centralized procurement shall, through the "Monitoring and Early Warning Platform for Production and Supply of Shortaged Drugs" (website), fill in the " Monitoring Report on Production and Supply of Drugs in Shortage of Pharmaceutical Industry Enterprises " and "National Centralized Procurement of Drug Production " respectively.
    Supply Monitoring Report"; key drug reserve enterprises in shortage fill in the " Statistical Table of Inventory Quantity of Shortage Drugs " through the "National Medical Reserve Management Information System"
    .
    Pharmaceutical and pharmaceutical enterprises Enterprise procurement of drugs and drugs
     
      Establish and improve the monitoring information reporting system, and must not be late or reported
     
      Manufacturers of drugs in short supply and selected drugs in centralized procurement are the first responsible person for reporting production reserve monitoring information.
    It is necessary to establish and improve the monitoring information submission work system; designate a person to fill in the production reserve data in a true, accurate, complete and timely manner without delay or delay.
    Refuse to report; cooperate with relevant departments in the investigation of drug shortage incidents, and provide information required for the investigation; set up production and supply inventory safety warning lines and prepare response plans
    .
     
      For enterprises that fail to comply with the requirements, they will be interviewed and required to rectify within a time limit as the case may be
    .
     
      Strengthen supervision and management.
    The local industry and information technology department, together with relevant departments, is responsible for the production and reserve monitoring of drugs in short supply and centralized procurement in the region, organizes enterprises to submit relevant data, audits the integrity and accuracy of data, and strengthens the supervision of drugs.
    Quality supervision and inspection, and urge production enterprises to implement their responsibilities for sufficient supply and stop production reports in accordance with the purchase agreement
    .
    For enterprises that fail to comply with the requirements, they will be interviewed and required to rectify within a time limit as the case may be
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.